The partners will combine their unique capabilities to jointly develop, offer, and deliver integrated services in the Antibody-Drug Conjugates (ADC) segment for the global pharmaceutical and biotechnology industries.
Agreement advances new therapies through Engitix’s unique focus on the extracellular matrix (ECM).
PolyPeptide's specialized peptide expertise and global multi-site network to strengthen Samsung Biologics' multi-modality and global manufacturing excellence.
Fujifilm Biotechnologies' Holly Springs, NC facility has been chosen as one of seven participants in the FDA's PreCheck Pilot Program, aimed at strengthening US pharmaceutical manufacturing and regulatory readiness.
Digital Innovation: a key driver of competitiveness and sustainability across the pharmaceutical industry.
Biopharma has never lacked ambition. The gap has always been between scientific promise and a product on a shelf. That's exactly where the most consequential innovation is happening now.
AI in pharma has moved past the hype cycle and into implementation. The organizations that pull ahead won't have the most sophisticated models — they'll have the strongest evidence foundation underneath them.
Marking 35 years of innovation, this collection celebrates how Enamine has grown from a regional supplier into a trusted global partner.
Lonza and Antharis Therapeutics announced an exclusive, target-specific licensing agreement to develop novel dual-payload ADCs targeting gastrointestinal (GI) cancers.
Recipharm announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharma and biotech companies with advanced sterile fill and finish services.
Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking the Italian biopharmaceutical group's largest deal to date.
Axplora is repositioning its Italian Farmabios site on high-potency APIs as UDCA production moves to its FDA-approved Vizag facility in India, consolidating supply and scaling for global demand.
Northway Biotech is finalizing the Baltic region's most advanced cell therapy center — a 3,500 m² facility at Vilnius City Innovation Industrial Park, set to open Q3 2025.
Precise, reproducible, and regulatory-ready: CE-based methods are redefining how scientists characterize therapeutic mAbs and ADCs across the biotherapeutic development pipeline.
Asahi Kasei Life Science has acquired the license rights for a novel antibody-drug conjugate (ADC) technology from The Noguchi Institute.
Acquisition strengthens US peptide manufacturing capabilities and broadens global expertise in complex peptide APIs
Hongene Biotech delivers end-to-end CDMO services for SiranBio's dual-target siRNA hepatitis B candidate, from raw materials through cGMP manufacturing, highlighting its capabilities in oligonucleotide therapeutics.
Bristol Myers Squibb licenses Lonza's SYNtecan linker-payload platform to advance an undisclosed ADC target, with Lonza eligible for upfront payments, milestones and royalties on resulting products.
Piramal Pharma Solutions opens a new payload-linker suite in Michigan as part of a $90 million US investment plan, bolstering its ADC manufacturing capabilities across sites in Riverview and Lexington.
All closing conditions satisfied for the acquisition of three small molecule sites in the US and Australia; closing to occur as of May 1, 2026. Adds highly demanded US-based manufacturing capacity to Siegfried's network.
In this CHEManager Leaders & Motivators interview, Frank Romanski, Lonza Capsugel, reflects on how strategy becomes execution and what resilience demands from teams,
The investment, its largest since its inception, demonstrates continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
Evonik is expanding its biotechnological production capacities at the Fermas site in Slovenská Ľupča with an investment of around €80 million
Byphar is Brenntag's new biopharma-focused brand designed to bring quality, efficiency and flexibility to every stage of biopharmaceutical manufacturing.
Acquisition includes industry-leading ADC platform, its clinically-validated tubutecan linker-payload technology, and next-generation platform to expand Gilead’s ADC capabilities.
Ofichem has unified its six brands under the single Ofichem name, creating a fully integrated, family-owned CDMO and pharmaceutical supplier.
On Demand | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.
The acquisition marks Samsung Biologics’ geographical diversification, establishing its first US manufacturing presence and expanding regional client support.
As discovery accelerates and throughput rises, digital transformation is becoming essential for chemistry labs. AI, robotics, and data growth must be orchestrated to boost productivity—rather than overwhelm the lab.
AI and evolving regulations set to transform biopharma operations in drug development and quality.
At CPhI Frankfurt, Christene Smith of CHEManager International interviews Axplora CCO Arul Ramadurai on navigating industry uncertainty and building strategic partnerships.
Sandoz has announced the creation of a new biosimilar development, manufacturing and supply unit.
Symbiosis Pharmaceutical Services has appointed experienced commercial leader Joanne Anderson as Chief Commercial Officer to drive global growth following recent capacity investments and expansion plans.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Forma Life Sciences launches as US-based contract development and manufacturing organization (CDMO) for oral solid dosage development and commercial manufacturing in Irvine, California.
